| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6992110 | ABBVIE | Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain |
Nov, 2021
(2 years ago) | |
| US7888342 | ABBVIE | Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain |
Nov, 2021
(2 years ago) | |
| US6602911 | ABBVIE | Methods of treating fibromyalgia |
Jan, 2023
(1 year, 3 months ago) | |
| US7994220 | ABBVIE | Milnacipran for the long-term treatment of fibromyalgia syndrome |
Sep, 2029
(5 years from now) | |
Savella is owned by Abbvie.
Savella contains Milnacipran Hydrochloride.
Savella has a total of 4 drug patents out of which 3 drug patents have expired.
Expired drug patents of Savella are:
- US6992110
- US7888342
- US6602911
Savella was authorised for market use on 14 January, 2009.
Savella is available in tablet;oral dosage forms.
Savella can be used as management of fibromyalgia, management of fibromyalgia (fm).
Drug patent challenges can be filed against Savella from 14 January, 2013.
The generics of Savella are possible to be released after 19 September, 2029.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 14, 2014 |
Drugs and Companies using MILNACIPRAN HYDROCHLORIDE ingredient
NCE-1 date: 14 January, 2013
Market Authorisation Date: 14 January, 2009
Treatment: Management of fibromyalgia (fm); Management of fibromyalgia
Dosage: TABLET;ORAL
SAVELLA family patents
